Monoamine neurotransmitter level increase

Monoamine neurotransmitter level increase refers to a physiological or pharmacological state characterized by elevated concentrations of biogenic amines—specifically serotonin, dopamine, and norepinephrine—within the synaptic cleft (StatPearls, 2023). This entry does not represent a single molecular target like a receptor or enzyme, but rather a therapeutic outcome or mechanism of action resulting from the modulation of various proteins such as transporters (SERT, NET, DAT) or metabolic enzymes (MAO) (PubMed, 2021). These neurotransmitters are essential for the regulation of mood, emotional response, cognitive function, and motor coordination (NIH, 2022). Pharmacological strategies to increase these levels are the primary approach for treating psychiatric and neurological conditions, including major depressive disorder and Parkinson's disease (StatPearls, 2023). However, precise therapeutic management is required, as excessive accumulation of these neurotransmitters can lead to life-threatening adverse events such as serotonin syndrome or hypertensive emergencies (Mayo Clinic, 2023). Consequently, while 'monoamine neurotransmitter level increase' is a critical therapeutic goal, it is a functional result of targeting specific molecular components of the monoaminergic system.

Other names

Monoamine elevationIncreased synaptic monoaminesMonoaminergic modulationElevation of biogenic amines

The increase is achieved through the inhibition of reuptake transporters such as the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), or through the inhibition of degradative enzymes like monoamine oxidase (MAO-A and MAO-B) (StatPearls, 2023; PubMed, 2021).